10x Genomics (TXG) Net Income towards Common Stockholders (2018 - 2025)
Historic Net Income towards Common Stockholders for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to -$16.3 million.
- 10x Genomics' Net Income towards Common Stockholders rose 6685.16% to -$16.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$43.5 million, marking a year-over-year increase of 7615.69%. This contributed to the annual value of -$43.5 million for FY2025, which is 7615.69% up from last year.
- According to the latest figures from Q4 2025, 10x Genomics' Net Income towards Common Stockholders is -$16.3 million, which was up 6685.16% from -$27.5 million recorded in Q3 2025.
- In the past 5 years, 10x Genomics' Net Income towards Common Stockholders registered a high of $34.5 million during Q2 2025, and its lowest value of -$93.0 million during Q3 2023.
- For the 5-year period, 10x Genomics' Net Income towards Common Stockholders averaged around -$35.3 million, with its median value being -$36.8 million (2024).
- In the last 5 years, 10x Genomics' Net Income towards Common Stockholders plummeted by 48322.48% in 2022 and then surged by 19113.65% in 2025.
- Over the past 5 years, 10x Genomics' Net Income towards Common Stockholders (Quarter) stood at -$18.4 million in 2021, then increased by 6.69% to -$17.2 million in 2022, then plummeted by 184.36% to -$49.0 million in 2023, then dropped by 0.16% to -$49.0 million in 2024, then soared by 66.85% to -$16.3 million in 2025.
- Its Net Income towards Common Stockholders was -$16.3 million in Q4 2025, compared to -$27.5 million in Q3 2025 and $34.5 million in Q2 2025.